Forum Topic News
  • Conversation: AZ, Lilly pull plug on Alzheimer’s disease trials

    • June 12, 2018 12:51 PM BST
      • Post(s)

      AZ, Lilly pull plug on Alzheimer’s disease trials

      Alzheimer’s disease research has taken another hit with the failure of AstraZeneca and Eli Lilly’s experimental (BACE) inhibitor lanabecestat.
      The firms said they would discontinue two Phase III trials of the experimental drug after an independent data monitoring committee found that they were unlikely to meet their primary endpoints.
      The AMARANTH trial randomised patients with early Alzheimer’s disease to receive lanabecestat, 20mg or 50mg, or placebo orally once daily for 104 weeks, to assess the drug’s effect on change from baseline on the 13-item Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog13).
      Read more:,_lilly_pull_plug_on_alzheimers_disease_trials_1239521

Add Reputation

Do you want to add reputation for this member by this post?

or cancel